UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-QSB/A

(X) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934



FOR THE QUARTER ENDED FEBRUARY 28, 2003

ALLERGY IMMUNO TECHNOLOGIES, INC.

|Delaware                                                       | 95-3937129                          
|-------------------------------------------------------------- | ------------------------------------
|(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)

|20462 Chartwell Center Drive, Cornelius, NC 28031                                           
|--------------------------------------------------------------------------------------------
|(Address of principal executive offices)                                                    
|                                                                                            
|Registrant's telephone number including area code:(704) 896-0202                            
|                                                                                            
|Securities registered under Section 12(b) of the Exchange Act: 
NONE                        
|Securities registered under Section 12(g) of the Exchange Act:
COMMON STOCK, PAR VALUE $.001

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES( ) NO (X)

Number of shares of the issuer's common stock, par value $.001, outstanding as of February 28, 2003: 17,978,948 shares.

Item 1.  FINANCIAL STATEMENTS

Allergy Immuno Technologies, Inc.Financial StatementsNine Month Period Ended February 28, 2003

Allergy Immuno Technologies, Inc.Financial StatementsNine and Three Month Periods Ended February 28, 2003, and 2002



Table Of Contents



|                                                                                                                 | Page
|---------------------------------------------------------------------------------------------------------------- | ----
|Balance Sheet (Unaudited) As of February 28, 2003                                                                | 1   
|Statements of Operations (Unaudited) For the Nine Month and Three Month Periods Ended February 28, 2003 and 2002 | 2   
|Statements of Shareholders' Deficit
    (Unaudited) For the Nine Month Period Ended February 28, 2003            | 3   
|Statements of Cash Flows (Unaudited) For the Nine Month Periods Ended February 28, 2003 and 2002                 | 4   
|Notes to Financial Statements                                                                                    | 5-6 
|Management's Discussion and Analysis of Financial Condition
    And Selected Financial Data                      | 7-9 

|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  | 1   
|--------------------------------------------------------------- | ---------------------------------- | --------------------------- | ------------------------------------------- |  | --------------------- | --------------------- | - | --------------------- |  |  | ----
|Allergy Immuno Technologies, Inc.                              
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Balance Sheet (Unaudited)                                      
|As of the Nine Month Period Ended february 28,                 
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  | 2003
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Assets                                                          |                                    |                             |                                             |  |                       |                       |   |                       | 
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Current Assets                                                  |                                    |                             |                                             |  |                       |                      
|                                                                | Cash and Cash Equivalents          |                             |                                             |  | $                   -
|                                                                | Net Accounts Receivable            |                             |                                             |  |                       | -                    
|                                                                | Inventory                          |                             |                                             |  |                       |                       |   | -                    
|                                                                | Prepaid and Other Current Assets   |                             |                                             |  | -                    
|                                                                |                                    | Total Current Assets        |                                             |  |                       |                       | -
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Long-Term Assets                                                |                                    |                             |                                             |  |                      
|                                                                | Net Fixed Assets                   |                             |                                             |  |                       | -                    
|                                                                | Net Intangible Assets              |                             |                                             |  |                       | -                    
|                                                                |                                    | Long-Term Assets            |                                             |  |                       |                       | -
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             | Total Assets                                |  |                       |                       |   | $                   -
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Liabilities and Shareholders' Deficit                           |                                    |                             |                                             | 
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Current Liabilities                                             |                                    |                             |                                             |  |                      
|                                                                | Accounts Payable                   |                             |                                             |  |                       | $                   -
|                                                                | Accrued Liabilities - Compensation |                             |                                             |  | -                    
|                                                                | Accrued Liabilities - Other        |                             |                                             |  | 87,929               
|                                                                | Notes Payable - Current (Note 3)   |                             |                                             |  | 225,282              
|                                                                |                                    | Total Current Liabilities   |                                             |  |                       | 313,211              
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Shareholders' Deficit                                           |                                    |                             |                                             |  |                      
|                                                                | Common Stock (Note 4)              |                             |                                             |  |                       | 17,979               
|                                                                | Additional-Paid-In-Capital         |                             |                                             |  | 1,898,929            
|                                                                | Retained Earnings                  |                             |                                             |  |                       | (2,230,119)          
|                                                                |                                    | Total Shareholders' Deficit |                                             |  |                       | (313,211)            
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             | Total Liabilities and Shareholders' Deficit |  |                       | $                   -
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|The accompanying notes are an integral part of these statements |                                   







|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       | 2
|--------------------------------------------------------------- | -------------------------- | ------------------------ | ---------------- | --------------------------- | ---------- | ------------------------- | ------------------------- | ----------------------- | ------------------------------- | ------------------------- | ------------------------------- | ----------------------- | ------------------------- | --------------------- | -
|Allergy Immuno Technologies, Inc.                               |                            |                          |                  |                            
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Statements of  Operations (Unaudited)                           |                            |                          |                  |                            
|                                                                |                            |                          |                  |                            
|                                                                |                            |                          |                  |                             |            |                           |                           |                         | Nine Months Ended 
February 28, |                           | Three Months Ended
February 28,
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                
|All Discontinued Operations                                     |                            |                          | 2003             |                             | 2002       |                           | 2003                      |                         | 2002                           
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Net Sales                                                       |                            |                          |                  |                             |            | $                       - |                           | $                41,453 |                                 | $                       - |                                 | $                12,682
|Cost of Sales                                                   |                            |                          |                  |                             | -          |                           | 57,638                    |                         | -                               |                           | 19,144                         
|                                                                | Gross Income (Loss)        |                          |                  | -                           |            | (16,185)                  |                           | -                       |                                 | (6,462)                  
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Operating Expenses                                              |                            |                          |                  |                             |            |                           |                           |                         |                                
|                                                                | General and Administrative |                          |                  | 87,929                      |            | 49,923                    |                           | 37,574                  |                                 | 15,696                   
|                                                                |                            | Total Operating Expenses |                  | 87,929                      |            | 49,923                    |                           | 37,574                  |                                 | 15,696                   
|                                                                |                            |                          | Operating Loss   |                             |            | (87,929)                  | -                         | (66,108)                |                                 | (37,574)                  |                                 | (22,158)               
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|                                                                |                            |                          | Net Other Income |                             |            | -                         |                           | 26                      |                                 | -                         |                                 | 22                     
|                                                                |                            |                          |                  | Loss Before Income Taxes    |            | (87,929)                  |                           | (66,082)                |                                 | (37,574)                  |                                 | (22,136)               
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|                                                                |                            |                          |                  | Income Tax Expense (Note 6) |            | -                         |                           | 800                     |                                 | -                         |                                 | 800                    
|                                                                |                            |                          |                  |                             | Net Loss   |                           |                           | $            (87,929)   |                                 | $            (66,882)     |                                 | $            (37,574)   |                           | $            (22,936)
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Per Share Data (basic and diluted):                             |                            |                          |                  |                             |            |                           |                           |                        
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Net Loss                                                        |                            |                          |                  |                             |            |                           | $                       - |                         | $                       -       |                           | $                       -       |                         | $                       -
|Weighted average number of common shares outstanding            | 17,978,948                 |                          | 17,170,390       |                             | 17,978,948 |                           | 17,170,390               
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|The accompanying notes are an integral part of these statements |                            |                          |                  |                             |            |                          







|                                                                |            |           |             |                   |             |                    |            |                    |           |       | 3           
|--------------------------------------------------------------- | ---------- | --------- | ----------- | ----------------- | ----------- | ------------------ | ---------- | ------------------ | --------- | ----- | ------------
|Allergy Immuno Technologies, Inc.                              
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|Statements of Shareholders' Deficit (Unaudited)                
|For the Nine Month Period Ended February 28, 2003              
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             | Common Stock       | Additional | Accumulated        |           | Total
|                                                                |            |           |             |                   |             |                    |            | Paid-In            | Income    |       | Shareholders
|                                                                |            |           |             |                   |             | Shares             | Amount     | Capital            | (Deficit) |       | (Deficit)   
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|May 31, 2002                                                    |            |           | 17,978,948  | $  17,979         | $ 1,898,929 | $     (2,142,190)  |            | $        (225,282)
|Net Loss                                                        |            |           |             |                   |             |                    | (87,929)   |                    | (87,929) 
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|February 28, 2003                                               | 17,978,948 | $  17,979 | $ 1,898,929 | $     (2,230,119) |             | $        (313,211)
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|The accompanying notes are an integral part of these statements |            |          







|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  | 4
|----------------------------------------------------- | --------------------------------------------------------------------------------------------------- | --------------------------------------------------------------- | --------------------------------------------------------- | ------------------- | ------ | ----------------------- | ------------------------- | -------------------- | -------------------- |  | -
|Allergy Immuno Technologies, Inc.                    
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|Statement of Cash Flows (Unaudited)                  
|For the Nine Month Period Ended February 28,         
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|All Discontinued Operations                           |                                                                                                     |                                                                 | 2003                                                      |                     | 2002  
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|Cash Flows Provided by (Used in) Operating Activities |                                                                                                     |                                                                 |                                                          
|                                                      | Net Loss                                                                                            |                                                                 |                                                           |                     |        | $              (87,929) |                           | $           (66,882)
|                                                      | Adjustments to reconcile net (loss) 
to net provided by (used in) cash used in operating activities |                                                                 |                                                           |                    
|                                                      |                                                                                                     |                                                                 |                                                          
|                                                      |                                                                                                     | Depreciation and Amortization                                   |                                                           |                     | -      |                         | 955                      
|                                                      |                                                                                                     | (Increase) Decrease in Accounts Receivable                      |                                                           | -                   |        | 3,442                  
|                                                      |                                                                                                     | (Increase) Decrease in Inventory                                |                                                           | -                   |        | 1,169                  
|                                                      |                                                                                                     | (Increase) Decrease in Prepaid and Other Current Assets         | -                                                         |                     | 2,352 
|                                                      |                                                                                                     | Increase (Decrease) in Accounts Payable and Accrued Liabilities | 87,929                                                    |                     | 34,224
|                                                      |                                                                                                     |                                                                 | Net Cash Flows Provided by (Used in) Operating Activities | -                   |        | (24,740)               
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|Cash Flows Provided by (Used in) Financing Activities |                                                                                                     |                                                                 |                                                          
|                                                      | Advances from affiliate                                                                             |                                                                 |                                                           | -                   |        | 16,190                 
|                                                      |                                                                                                     | Net Cash Flows Provided by (Used in) Investing Activities       | -                                                         |                     | 16,190
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|                                                      |                                                                                                     |                                                                 | Net Cash Flows                                            |                     |        | -                       |                           | (8,550)             
|                                                      |                                                                                                     |                                                                 | Cash, Beginning of Period                                 |                     |        | -                       |                           | 9,455               
|                                                      |                                                                                                     |                                                                 |                                                           | Cash, End of Period |        |                         | $                       - |                      | $                905





> 5

Allergy Immuno Technologies, Inc.Notes To Financial Statements February 28, 2003



1. Summary Of Significant Accounting Policies

Reference is made to Note 1 of the Notes to Financial Statements contained in the
Company's Annual Report on form 10-KSB for the fiscal year ended May 31, 2002, for a summary of significant accounting policies utilized by the Company and new accounting pronouncements.2. Disclosures

The accompanying balance sheet at February 28, 2003, and the statements of operations, cash flows and
shareholders' deficit for the three month and nine month periods ended February 28, 2003 and 2002 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. In our opinion, the condensed consolidated financial statements include all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position, results of operations and cash flows for each interim period shown.3. Limitation on Results of OperationsResults of operations for the interim periods covered by this Report may not necessarily be indicative of results of operations for the full fiscal year.4. Notes PayableAllergy Immuno Technologies, Inc. has an outstanding demand promissory note for services rendered and expenses advanced by the former parent company, Biomerica.  The note is for $225,282 and accrues interest at 7% compounded annually until payment on the note is made.  As no term is specified a schedule of payments is not available.  The note was sold on May 30, 2002 to LDM, Holdings Inc.

> 6

Allergy Immuno Technologies, Inc.Notes To Financial Statements November 30, 2002(Continued)

5.     Net Loss Per ShareThe FASB has issued Statement of Financial Accounting Standards No. 128 (SFAS 128), "Earnings Per Share."  SFAS 128 is primarily a disclosure standard which requires public companies to present basic earnings per share (EPS) and, if applicable, diluted earnings per share, instead of primary and fully diluted earnings per share.  Basic EPS is computed by dividing net income for the year by the weighted average number of shares of common stock outstanding during the year.  Diluted EPS is computed by dividing net (loss) income for the year by weighted average number of shares of common stock and common stock equivalents outstanding during the year.
The following table illustrates the required disclosure of the reconciliation of the numerators and denominators of the basic and diluted EPS computations.



|                                                                     |  | Income              |  | Shares        |  | Per Share   
|-------------------------------------------------------------------- |  | ------------------- |  | ------------- |  | ------------
|For the Nine Month Period Ended February 28, 2003                    |  | (Numerator)         |  | (Denominator) |  | Amount      
|                                                                     |  |                     |  |               |  |             
|Basic EPS                                                            |  |                     |  |               |  |             
|Loss available to common shareholders                                |  | $        (87,929)   |  | 17,978,948    |  | $          -
|                                                                     |  |                     |  |               |  |             
|Effect of Dilutive Securities                                        |  |                     |  |               |  |             
|Options                                                              |  | $                 - |  | -             |  | $          -
|                                                                     |  |                     |  |               |  |             
|Diluted EPS                                                          |  |                     |  |               |  |             
|Loss available to common shareholders plus 
     assumed conversions |  | $        (87,929)   |  | 17,978,948    |  | $          -



|                                                                     |  | Loss                |  | Shares        |  | Per Share   
|-------------------------------------------------------------------- |  | ------------------- |  | ------------- |  | ------------
|For the Nine Month Period Ended February 28, 2002                    |  | (Numerator)         |  | (Denominator) |  | Amount      
|                                                                     |  |                     |  |               |  |             
|Basic EPS                                                            |  |                     |  |               |  |             
|Loss available to common shareholders                                |  | $        (66,882)   |  | 17,170,390    |  | $          -
|                                                                     |  |                     |  |               |  |             
|Effect of Dilutive Securities                                        |  |                     |  |               |  |             
|Options                                                              |  | $                 - |  | -             |  | $          -
|                                                                     |  |                     |  |               |  |             
|Diluted EPS                                                          |  |                     |  |               |  |             
|Loss available to common shareholders plus 
     assumed conversions |  | $        (66,882)   |  | 17,170,390    |  | $          -

6.	Going Concern

> The accompanying financial statements have been prepared assuming the Company will continue as a going concern.  During the fiscal year ended May 31, 2002, the Company discontinued all operations and these conditions raise substantial doubt about the
> Company's ability to continue as a going concern.7. Subsequent Events
> 
> At the end of the reporting period, we owed our principal shareholder, LDM Holdings, Inc., the sum of $313,211. Of this sum, $225,282 is the principal amount on a note payable, and $87,929 is due to accrued liabilities. On March 28, 2003, our board voted to convert $275,637 of our total obligation to LDM Holdings into 13,781,859 shares of our common stock, a price of $0.02 per share.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THE FOLLOWING DISCUSSION OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF THE COMPANY SHOULD BE READ IN CONJUNCTION WITH THE
FINANCIAL STATEMENTS AND NOTES THERETO INCLUDED ELSEWHERE IN THIS REPORT.

THIS DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THESE FORWARD-LOOKING STATEMENTS AS A RESULT OF CERTAIN FACTORS, INCLUDING, BUT NOT LIMITED TO, COMPETITION AND OVERALL MACRO- ECONOMIC CONDITIONS.General

The Company formerly generated revenue by providing clinical testing services to doctors, laboratories and pharmaceutical firms in specialized areas of allergy and immunology determinations. However, in March of 2002, Allergy's board resolved to terminate Allergy's operations.Plan of OperationAllergy has had no business operation since March of 2002. Allergy's present operational plan is to find a suitable operating company with which Allergy can merge, or to purchase the assets of a business with operations. Our President, Dean Martin, devotes an average of 15 hours per week to this effort, and is presently our sole employee, except for outside accountants and an outside attorney. Mr. Martin is not paid a salary for his efforts. We do not plan any product or service research and development in the pursuit of our plan. Similarly, we do not expect to purchase any plant or significant equipment. We do not expect any significant changes in the number of our employees.

Our only expenses of operation are general and administrative expenses, which are almost solely comprised of auditor fees and lawyer fees. We expect that we will expend $70,000 in fiscal 2003 on general and administrative expenses. Our cash requirements are presently satisfied by loans from our principal shareholder. Our principal shareholder intends to satisfy our cash requirements in this manner until August 30, at which time we may need to raise additional funds to pursue our plan of seeking a merger partner.Results of Operations (Operations Are Discontinued)NINE MONTHS ENDED FEBRUARY 28, 2003, COMPARED TO NINE MONTHS ENDED FEBRUARY 28, 2002

Revenues for the nine months ended February 28, 2003 were $0 as compared to $41,453 in the prior nine month period. The Company's decision to phase out its operations contributed solely to this 100% decrease in revenue over the prior period. Cost of sales was reduced from $57,638 to $0 as compared to the previous period. Again, our discontinuation of operations contributed solely to the elimination of cost of sales.

General and administrative expenses increased from $49,923 for the nine months ended February 28, 2002 to $87,929 for the comparable period in 2003, a 76% increase. Substantially all of the 76 percent increase can be attributed to our change of auditors in August of 2002. The change in auditors caused us to incur duplicate charges. The company had no research and development expenses in either period.Liquidity and Capital ResourcesAs of February 28, 2003, the Company had cash of $0 compared to $905 for the previous nine month period.
The Company's March 2002 decision to cease Company operations has and will significantly impact the Company's liquidity in the following ways:

> *The Company has reduced its administrative and operating expenses.
> *The Company has eliminated expenses related to its cost of sales.
> *The Company will continue to have reduced administrative and operating expenses.
> *The Company no longer has a source of revenue, and its sales will be $0 until it develops operations or finds a suitable operating company with which it can merge.
> *The Company is presently operating at a loss, and will continue to operate at a loss until it develops operations or finds a suitable operating company with which it can merge.
> *Management believes that losses will continue during fiscal 2003. As discussed above under the heading "Plan of Operation," our cash requirements are presently satisfied by loans from our principal shareholder. Our principal shareholder intends to satisfy our cash requirements in this manner until August 30, at which time we may need to raise additional funds to pursue our plan of seeking a merger partner.

Going ConcernThe accompanying financial statements have been prepared assuming the Company will continue as a going concern. We have no operations, and thus no source of revenue. We continue to incur operating expenses. We had substantial working capital and shareholders' deficits at May 31, 2002. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

There can be no assurances that the Company will be able to successfully implement its plans, including generating profitable operations, generating positive cash flows from operations and obtaining additional debt and equity capital to meet present and future working capital demands.Research and DevelopmentDuring fiscal 2002 the Company did not spend any funds on research and development. The Company does not expect to engage in further research and development with respect to its former operations.ManufacturingAllergy does not currently perform any manufacturing.Item 3. LEGAL PROCEEDINGS

We are not a party to any legal proceedings.

Item 4. CHANGES IN SECURITIES AND USE OF PROCEEDS

The rights of security holders have not been materially modified during the reporting period.Item 5. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERSNo matters have been submitted to security holders during the reporting period.Item 6. EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. Regulations under the Securities Exchange Act of 1934 require public companies to maintain "disclosure controls and procedures," which are defined to mean a company's controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Our chief executive and financial officer, based on his evaluation of the effectiveness of our disclosure controls and procedures within 90 days before the filing date of this report, concluded that our disclosure controls and procedures were effective for this purpose.

(b) Changes in Internal Controls. There were no significant changes in our internal controls or, to our knowledge, in other factors that could significantly affect our internal controls subsequent to the evaluation date referred to above.Item 7. EXHIBITS AND REPORTS ON FORM 8-Ka. Reports on Form 8-K.

> We filed no reports on form 8-K during the reporting period.

b. Exhibits:

> Exhibit 99.1. Certification of Chief Executive Officer
>   pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Dated: April 22, 2003



ALLERGY IMMUNO TECHNOLOGIES, INC.

Registrant

By/s/ Dean Martin____________________________
Dean Martin,
President, Secretary and Principal Financial Officer



CERTIFICATION



I, Dean Martin, certify that:

1. I have reviewed this quarterly report on Form 10-QSB/A of Allergy Immuno Technologies, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report.

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and I have:

> a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
> b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
> c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

> a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
> b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.



Dated: April 22, 2003



By /s/ Dean Martin
____________________________
Dean Martin,
President, Secretary and Principal Financial Officer





Exhibit 99.1. Certification of Chief Executive Officer and Chief
Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)



In connection with the Quarterly Report of Allergy Immuno
Technologies, Inc., a Delaware corporation (the "Company"), on Form
10-QSB/A for the period ending February 28, 2003 as filed with the Securities and Exchange Commission (the
"Report"), I, Dean Martin, Chief Executive Officer and Principal
Financial Officer of the Company, certify, pursuant to Sec. 906 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in
all material respects, the financial condition and result of operations of the
Company.

Date: April 22, 2003/s/ Dean Martin
_____________________
Dean Martin,
President, Secretary and Principal Financial Officer